Literature DB >> 3007676

The role of myo-inositol in multiple sclerosis.

G B Young, W J Hader, M Hiscock, K G Warren, D Logan.   

Abstract

Myo-inositol was given orally to nine multiple sclerosis patients and nine healthy control subjects. Pattern reversal evoked potential testing was used to assess its effect. The principal positive wave increased in amplitude, duration and area in a dose-dependent manner in the multiple sclerosis group compared with controls. Cerebrospinal fluid concentrations of myo-inositol in multiple sclerosis and controls were similar. The significance of these observations is discussed in relation to recent discoveries in inositol phospholipid function.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3007676      PMCID： PMC1028725          DOI： 10.1136/jnnp.49.3.265

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  26 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Reduced neuromuscular transmission safety factor in multiple sclerosis.

Authors:  A Eisen; R Yufe; D Trop; I Campbell
Journal:  Neurology       Date:  1978-06       Impact factor: 9.910

3.  The effect of anticonvulsant drugs which induce liver microsomal enzymes on derived and ingested phenobarbitone levels.

Authors:  N Callaghan; M Feely; F Duggan; M O'Callaghan; J Seldrup
Journal:  Acta Neurol Scand       Date:  1977-07       Impact factor: 3.209

4.  Diabetic polyneuropathy: the importance of insulin deficiency, hyperglycemia and alterations in myoinositol metabolism in its pathogenesis.

Authors:  A I Winegrad; D A Greene
Journal:  N Engl J Med       Date:  1976-12-16       Impact factor: 91.245

5.  Visual evoked response in diagnosis of multiple sclerosis.

Authors:  A M Halliday; W I McDonald; J Mushin
Journal:  Br Med J       Date:  1973-12-15

6.  Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors.

Authors:  S M Crain; M B Bornstein
Journal:  Exp Neurol       Date:  1975-10       Impact factor: 5.330

7.  Conduction through demyelinated plaques in multiple sclerosis: computer simulations of facilitation by short internodes.

Authors:  S G Waxman; M H Brill
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

8.  Inositol in multiple sclerosis.

Authors:  V Holm
Journal:  Arch Neurol       Date:  1978-07

9.  Multiple sclerosis: serum factor producing reversible alterations in bioelectric responses.

Authors:  J A Cerf; G Carels
Journal:  Science       Date:  1966-05-20       Impact factor: 47.728

10.  Anti-synaptic antibody in allergic encephalomyelitis. II. The synapse-blocking effects in tissue culture of demyelinating sera from experimental allergic encephalomyelitis.

Authors:  C E Lumsden; L Howard; S R Aparicio; M Bradbury
Journal:  Brain Res       Date:  1975-08-08       Impact factor: 3.252
View more
  2 in total

1.  Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.

Authors:  Fay Probert; Tianrong Yeo; Yifan Zhou; Megan Sealey; Siddharth Arora; Jacqueline Palace; Timothy D W Claridge; Rainer Hillenbrand; Johanna Oechtering; David Leppert; Jens Kuhle; Daniel C Anthony
Journal:  Brain Commun       Date:  2021-04-19

2.  Altered Plasma Metabolic Profiles in Chinese Patients With Multiple Sclerosis.

Authors:  Fan Yang; Shao-Chang Wu; Zong-Xin Ling; Shan Chao; Li-Juan Zhang; Xiu-Mei Yan; Lin He; Li-Mei Yu; Long-You Zhao
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.